Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Boehringer Ingelheim Venture Fund (BIVF)

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF's focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, in regenerative medicine or gene therapy. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy. BIVF takes an active role with its portfolio companies - delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has €200 million under management and currently supervises a portfolio of more than 20 companies. *

 

Period Start 2010-03-01 established
Products Industry venture capital
  Industry 2 pharmaceutical
Persons Person Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)
  Person 2 Kostka, Marcus (Boehringer 201410 Director at Boehringer Ingelheim Venture Fund)
     
Region Region Ingelheim
  Country Germany
  Street 173 Binger Str.
  City 55216 Ingelheim
  Tel +49-6132-77-8740
    Address record changed: 2010-09-18
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 200,000,000 (capital under management 2018-01-04)
     
    * Document for �About Section�: Rewind Therapeutics. (1/4/18). "Press Release: Rewind Therapeutics Secures 15.2m Euro to Develop Novel Remyelination Therapies". Leuven.
     
   
Record changed: 2018-12-04

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Boehringer Ingelheim Venture Fund (BIVF)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top